Marshall W. Fordyce

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 593 citations

Treatment And Prevention, Medicine, Antiviral Drug Development +10

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

Peter Ruane, Edwin DeJesus, Daniel Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2013 · 304 citations

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

Paul E. Sax, Andrew Zolopa, Indira Brar et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2014 · 206 citations

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

Anton Pozniak, José Ramón Arribas, Joseph Gathe et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 184 citations · Full text

Brief Report

David A. Wohl, Shinichi Oka, Nathan Clumeck et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2016 · 178 citations · Full text

Double-blinded Phase 3, Initial Hiv-1 Treatment, Taf Arm +13